1. Home
  2. MNSB vs MDWD Comparison

MNSB vs MDWD Comparison

Compare MNSB & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

HOLD

Current Price

$24.20

Market Cap

164.1M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$12.27

Market Cap

162.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNSB
MDWD
Founded
2003
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.1M
162.2M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
MNSB
MDWD
Price
$24.20
$12.27
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $30.67
AVG Volume (30 Days)
21.4K
★ 78.8K
Earning Date
10-26-2026
11-19-2026
Dividend Yield
★ 1.68%
N/A
EPS Growth
★ 210.00
N/A
EPS
★ 1.05
N/A
Revenue
★ $135,615,000.00
N/A
Revenue This Year
N/A
$39.60
Revenue Next Year
N/A
$34.34
P/E Ratio
$22.61
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$17.86
$11.84
52 Week High
$25.87
$19.70

Technical Indicators

Market Signals
Indicator
MNSB
MDWD
Relative Strength Index (RSI) 46.64 41.90
Support Level $24.24 N/A
Resistance Level $25.29 $14.06
Average True Range (ATR) 0.54 0.50
MACD -0.07 -0.05
Stochastic Oscillator 48.28 21.79

Price Performance

Historical Comparison
MNSB
MDWD

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: